All In Biotech

Drug Trial Radar · NCT06462612

Study of Lumateperone in the Treatment of Patients With Bipolar Mania

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Lumateperone in the Acute Treatment of Patients With Manic Episodes or Manic Episodes With Mixed Features Associated With Bipolar I Disorder (Bipolar Mania)

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 351 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

351

Actual

Start

Jul 17, 2024

Primary completion

May 15, 2026

Study completion May 20, 2026

Sponsor

Lead sponsor
Intra-Cellular Therapies, Inc.Industry
Sponsor type
Industry
First posted
Jun 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

Conditions

  • Bipolar Disorder, Manic

Interventions

  • LumateperoneDrug

    Lumateperone 42 mg capsules administered orally, once daily

  • PlaceboDrug

    Matching capsules administered orally, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Young Mania Rating Scale (YMRS)Time frame: Week 3

Locations

35 sites in 4 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Bentonville, Arkansas

  • Clinical Site

    Little Rock, Arkansas

  • Clinical Site

    Anaheim, California

  • Clinical Site

    Cerritos, California

  • Clinical Site

    Orange, California

  • Clinical Site

    Torrance, California

  • Clinical Site

    Hialeah, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Miami Lakes, Florida

  • Clinical Site

    Miami Lakes, Florida

  • Clinical Site

    Tampa, Florida

  • Clinical Site

    West Palm Beach, Florida

  • Clinical Site

    Atlanta, Georgia

  • Clinical Site

    Stockbridge, Georgia

  • Clinical Site

    Chicago, Illinois

  • Clinical Site

    Chicago, Illinois

  • Clinical Site

    Gaithersburg, Maryland

  • Clinical Site

    Glen Oaks, New York

  • Clinical Site

    Cincinnati, Ohio

  • Clinical Site

    Richardson, Texas

  • Clinical Site

    Burgas, Bulgaria

  • Clinical Site

    Kazanlak, Bulgaria

  • Clinical Site

    Plovdiv, Bulgaria

  • Clinical Site

    Sliven, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Brasov, Romania

  • Clinical Site

    Bucharest, Romania

  • Clinical Site

    Iași, Romania

  • Clinical Site

    Belgrade, Serbia

  • Clinical Site

    Kovin, Serbia

  • Clinical Site

    Kragujevac, Serbia

  • Clinical Site

    Niš, Serbia

  • Clinical Site

    Novi Kneževac, Serbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.